OncLive SOSS

Expert Perspectives & Insights into the Evolving Treatment of Refractory Metastatic Colorectal Cancer - Episode 3

Fruquintinib MoA and Toxicity Profile Overview

February 29, 2024

Aparna R. Parikh, MD, Marwan G. Fakih, MD, Richard Kim, MD, Scott Paulson, MD, Mark A. Lewis, MD, Joleen M. Hubbard, MD

Key safety considerations for the use of fruquintinib are explored.

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time 0:00

EP. 1: Overview of Current mCRC Treatment Landscape

EP. 2: Evaluating 3L Treatment Landscape Evolution

EP. 3: Fruquintinib MoA and Toxicity Profile Overview

EP. 4: Compounding Impact of TAS-102 and Bevacizumab in mCRC Treatment

EP. 5: FRESCO-2 Study Highlights

EP. 6: Dose Modifications and Tolerability Associated with mCRC Treatment Regimens

EP. 7: Utilizing RWE to Derive Optimal Treatment Strategy for Refractory mCRC

EP. 8: Consideration for Fruquintinib Dosing and Titration

EP. 9: Fatigue Associated with Bevacizumab, Fruquintinib, TAS-102 Therapies

EP. 10: Identifying Ideal Candidates for Triplet Therapy in mCRC Treatment

EP. 11: Considerations for Platinum-based Therapy

EP. 12: Treatment Sequencing for Refractory mCRC and SUNLIGHT Study Analysis

EP. 13: Real-World Data Surrounding Sequencing Strategies for Refractory mCRC

EP. 14: Data Surrounding Treatment for MSI-high Patients from ASCO 2024

EP. 15: Unmet Needs Surrounding mCRC Treatment

EP. 16: Anticipating Key Studies and Pipeline Treatments in mCRC Landscape

x